Psoriasis is associated with increased cardiovascular risk that is not captured by traditional pro-inflammatory biomarkers.To investigate the relationship between psoriasis area and severity index (PASI), circulating pro-inflammatory biomarkers, and vascular …

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease with a complex etiology including genetic and environmental risk factors.1 Obesity has been associated with increased AD risk and severity,2 …

Hand eczema (HE) is a heterogeneous and burdensome disorder.To characterize the clinical characteristics, etiologies and allergen relevance in adults with HE referred for patch testing.Retrospective analysis (2000-2016) of North American …

Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time-dependent drug survival in psoriasis and the effect …

Scabies is a parasitic skin disease. Its clinical diagnosis may be challenging.In a prospective observational study, we enrolled all consecutive patients ≥16 years of age with a presumptive diagnosis of scabies …

Cutaneous tuberculosis (CTB) rarely involves the ear as the primary site, but while diagnosing and treating ear infections, it should be considered a differential diagnosis in a tropical country such …

Conjunctivitis and several other ocular surface diseases (OSDs) have been linked to atopic dermatitis (AD) and its treatment.To examine the association between AD, conjunctivitis and other OSDs.A systematic review and …

Information on recent trends in overall and subgroup incidences in psoriasis is limited.To estimate current incidence of psoriasis in the U.S., compare incidences among demographic subgroups, and evaluate recent disease …

While superficial spreading melanomas (SSM) are diagnosed as thinner lesions, nodular melanomas (NM) have a more rapid growth rate and are biologically more aggressive compared to other histologic subtypes.To determine …

To report efficacy and safety of the approved IXE dose over 5 years from UNCOVER-3. (NCT01646177).Patients (N=1346) were randomized 1:2:2:2 to receive subcutaneous injections of placebo, etanercept 50 mg twice …